Anemia, ineffective erythropoiesis, and hepcidin: Interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia

Hematology/Oncology Clinics of North America

Volumn 24, Issue 6, 2010, Pages 1089-1107

  Gardenghi, Sara ^a   Grady, Robert W ^a   Rivella, Stefano ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Thalassemia; Hepcidin; Ineffective erythropoiesis; Iron overload; Jak2; Splenomegaly

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMATOLOGIC AGENT; HEPCIDIN; HEPCIDIN AGONIST; IRON; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; BETA THALASSEMIA; DRUG MECHANISM; ERYTHROID CELL; ERYTHROPOIESIS; HUMAN; IRON ABSORPTION; IRON INTAKE; IRON METABOLISM DISORDER; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANEMIA; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-THALASSEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; IRON; IRON OVERLOAD; RECEPTORS, ERYTHROPOIETIN;

EID: 78249289938     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.08.003     Document Type: Review

References (109)

1. Cooley T.B., Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925, 37:29.
2. Weatherall D.J. Single gene disorders or complex traits: lessons from the thalassaemias and other monogenic diseases. BMJ 2000, 321(7269):1117-1120.
3. Weatherall D.J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001, 2(4):245-255.
4. Forget B.G. Molecular mechanisms of β thalassemia. Disorders of hemoglobin: genetics, pathophysiology and clinical management 2001, 252-276. Cambridge University Press, Cambridge (UK). M.H. Steinberg, B.G. Forget, D.R. Higgs (Eds.).
5. Steinberg M.H., Forget B.G., Higgs D.R., et al. Disorders of hemoglobin: genetics, pathophysiology and clinical management 2009, Cambridge University Press, Cambridge (UK), p. 1-826. 2nd edition.
6. Cao A., Pintus L., Lecca U., et al. Control of homozygous beta-thalassemia by carrier screening and antenatal diagnosis in Sardinians. Clin Genet 1984, 26(1):12-22.
7. Vichinsky E.P. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci 1998, 850:344-348.
8. Wonke B. Clinical management of beta-thalassemia major. Semin Hematol 2001, 38(4):350-359.
9. Cohen A.R., Galanello R., Pennell D.J., et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004, 14-34.
10. Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol 1995, 32(4):262-268.
11. Giardina P.J., Grady R.W. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001, 38(4):360-366.
12. Crary S.E., Buchanan G.R. Vascular complications after splenectomy for hematologic disorders. Blood 2009, 114(14):2861-2868.
13. Eldor A., Rachmilewitz E.A. The hypercoagulable state in thalassemia. Blood 2002, 99(1):36-43.
14. Taher A., Mehio G., Isma'eel H., et al. Stroke in thalassemia: a dilemma. Am J Hematol 2008, 83(4):343.
15. Rivella S., Rachmilewitz E. Future alternative therapies for beta-thalassemia. Expert Rev Hematol 2009, 2(6):685.
16. Breda L., Gambari R., Rivella S. Gene therapy in thalassemia and hemoglobinopathies. Mediterranean Journal of Hematology and Infectious Diseases 2009, 1(1). e2009008.
17. Skow L.C., Burkhart B.A., Johnson F.M., et al. A mouse model for beta-thalassemia. Cell 1983, 34(3):1043-1052.
18. Curcio M.J., Kantoff P., Schafer M.P., et al. Compensatory increase in levels of beta minor globin in murine beta-thalassemia is under translational control. J Biol Chem 1986, 261(34):16126-16132.
19. De Franceschi L., Daraio F., Filippini A., et al. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. Haematologica 2006, 91(10):1336-1342.
20. Yang B., Kirby S., Lewis J., et al. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A 1995, 92(25):11608-11612.
21. Ciavatta D.J., Ryan T.M., Farmer S.C., et al. Mouse model of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc Natl Acad Sci U S A 1995, 92(20):9259-9263.
22. Rivella S., May C., Chadburn A., et al. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta -globin gene transfer. Blood 2003, 101(8):2932-2939.
23. Wu H., Liu X., Jaenisch R., et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83(1):59-67.
24. D'Andrea A., Fasman G., Wong G., et al. Erythropoietin receptor: cloning strategy and structural features. Int J Cell Cloning 1990, 8(Suppl 1):173-180.
25. D'Andrea A.D., Lodish H.F., Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 1989, 57(2):277-285.
26. Li K., Miller C., Hegde S., et al. Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with kit. J Biol Chem 2003, 278(42):40702-40709.
27. Menon M.P., Fang J., Wojchowski D.M. Core erythropoietin receptor signals for late erythroblast development. Blood 2006, 107(7):2662-2672.
28. Menon M.P., Karur V., Bogacheva O., et al. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 2006, 116(3):683-694.
29. von Lindern M., Zauner W., Mellitzer G., et al. The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood 1999, 94(2):550-559.
30. Fang J., Menon M., Kapelle W., et al. EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts. Blood 2007, 110(7):2361-2370.
31. Socolovsky M., Murrell M., Liu Y., et al. Negative autoregulation by FAS mediates robust fetal erythropoiesis. PLoS Biol 2007, 5(10):e252.
32. James C. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?. Hematology Am Soc Hematol Educ Program 2008, 69-75.
33. Levine R.L. Mechanisms of mutations in myeloproliferative neoplasms. Best Pract Res Clin Haematol 2009, 22(4):489-494.
34. Garcon L., Rivat C., James C., et al. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006, 108(5):1551-1554.
35. Socolovsky M., Nam H., Fleming M.D., et al. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001, 98(12):3261-3273.
36. Socolovsky M., Fallon A.E., Wang S., et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999, 98(2):181-191.
37. Dolznig H., Grebien F., Deiner E.M., et al. Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. Oncogene 2006, 25(20):2890-2900.
38. Kerenyi M.A., Grebien F., Gehart H., et al. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood 2008, 112(9):3878-3888.
39. Zhu B.M., McLaughlin S.K., Na R., et al. Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood 2008, 112(5):2071-2080.
40. Finch C.A., Deubelbeiss K., Cook J.D., et al. Ferrokinetics in man. Medicine 1970, 49(1):17-53.
41. Centis F., Tabellini L., Lucarelli G., et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood 2000, 96(10):3624-3629.
42. Mathias L.A., Fisher T.C., Zeng L., et al. Ineffective erythropoiesis in beta-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp Hematol 2000, 28(12):1343-1353.
43. Yuan J., Angelucci E., Lucarelli G., et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood 1993, 82(2):374-377.
44. Libani I.V., Guy E.C., Melchiori L., et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in {beta}-thalassemia. Blood 2008, 112(3):875-885.
45. Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009, 16(3):187-194.
46. Wang Y.L., Vandris K., Jones A., et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia 2008, 22(6):1289.
47. Fibach E., Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008, 8(7):609-619.
48. Marinkovic D., Zhang X., Yalcin S., et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007, 117(8):2133-2144.
49. Callens C., Coulon S., Naudin J., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207(4):731-750.
50. Abdel-Wahab O., Levine R.L. Metabolism and the leukemic stem cell. J Exp Med 2010, 207(4):677-680.
51. Li H., Rybicki A.C., Suzuka S.M., et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010, 16(2):177-182.
52. Andrews N.C. Disorders of iron metabolism. N Engl J Med 1999, 341(26):1986-1995.
53. Krause A., Neitz S., Magert H.J., et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000, 480(2-3):147-150.
54. Park C.H., Valore E.V., Waring A.J., et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001, 276(11):7806-7810.
55. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
56. Nemeth E., Preza G.C., Jung C.L., et al. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006, 107(1):328-333.
57. Pigeon C., Ilyin G., Courselaud B., et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001, 276(11):7811-7819.
58. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110(7):1037-1044.
59. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113(9):1271-1276.
60. Nemeth E., Valore E.V., Territo M., et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101(7):2461-2463.
61. Wrighting D.M., Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108(9):3204-3209.
62. Nicolas G., Viatte L., Bennoun M., et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002, 29(3):327-335.
63. Vokurka M., Krijt J., Sulc K., et al. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006, 55(6):667-674.
64. Lebron J.A., West A.P., Bjorkman P.J. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999, 294(1):239-245.
65. Schmidt P.J., Toran P.T., Giannetti A.M., et al. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008, 7(3):205-214.
66. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13(4):399-408.
67. Kawabata H., Yang R., Hirama T., et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999, 274(30):20826-20832.
68. Goswami T., Andrews N.C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 2006, 281(39):28494-28498.
69. Gao J., Chen J., Kramer M., et al. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009, 9(3):217-227.
70. Wang R.H., Li C., Xu X., et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005, 2(6):399-409.
71. Babitt J.L., Huang F.W., Wrighting D.M., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38(5):531-539.
72. Babitt J.L., Huang F.W., Xia Y., et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007, 117(7):1933-1939.
73. Kautz L., Meynard D., Monnier A., et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008, 112(4):1503-1509.
74. Xia Y., Babitt J.L., Sidis Y., et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008, 111(10):5195-5204.
75. Meynard D., Kautz L., Darnaud V., et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009, 41(4):478-481.
76. Ramey G., Deschemin J.C., Vaulont S. Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica 2009, 94(6):765-772.
77. Calzolari A., Raggi C., Deaglio S., et al. TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 2006, 119(Pt 21):4486-4498.
78. Andrews N.C. Forging a field: the golden age of iron biology. Blood 2008, 112(2):219-230.
79. Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009, 122(2-3):78-86.
80. Finberg K.E., Heeney M.M., Campagna D.R., et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008, 40(5):569-571.
81. Du X., She E., Gelbart T., et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008, 320(5879):1088-1092.
82. Silvestri L., Pagani A., Nai A., et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008, 8(6):502-511.
83. Lin L., Goldberg Y.P., Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005, 106(8):2884-2889.
84. Finberg K.E., Whittlesey R.L., Fleming M.D., et al. Downregulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 2010, 115(18):3817-3826.
85. Huang F.W., Pinkus J.L., Pinkus G.S., et al. A mouse model of juvenile hemochromatosis. J Clin Invest 2005, 115(8):2187-2191.
86. Adamsky K, Weizer O, Amariglio N, et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004, 124(1):123-124.
87. Pak M., Lopez M.A., Gabayan V., et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006, 108(12):3730-3735.
88. Fiorelli G., Fargion S., Piperno A., et al. Iron metabolism in thalassemia intermedia. Haematologica 1990, 75(Suppl 5):89-95.
89. Gardenghi S., Marongiu M.F., Ramos P., et al. Ineffective erythropoiesis in {beta}-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007, 109(11):5027-5035.
90. Weizer-Stern O., Adamsky K., Amariglio N., et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol 2006, 135(1):129-138.
91. Weizer-Stern O., Adamsky K., Amariglio N., et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Am J Hematol 2006, 81(7):479-483.
92. Origa R., Galanello R., Ganz T., et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007, 92(5):583-588.
93. Kearney S.L., Nemeth E., Neufeld E.J., et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007, 48(1):57-63.
94. Papanikolaou G., Tzilianos M., Christakis J.I., et al. Hepcidin in iron overload disorders. Blood 2005, 105(10):4103-4105.
95. Kattamis A., Papassotiriou I., Palaiologou D., et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006, 91(6):809-812.
96. Jenkins Z.A., Hagar W., Bowlus C.L., et al. Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 2007, 24(4):237-243.
97. Adamsky K., Weizer O., Amariglio N., et al. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004, 124(1):123-124.
98. Rechavi G., Rivella S. Regulation of iron absorption in hemoglobinopathies. Curr Mol Med 2008, 8(7):646-662.
99. de Franceschi L., Turrini F., Honczarenko M., et al. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica 2004, 89(11):1287-1298.
100. Tanno T., Porayette P., Sripichai O., et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009, 114(1):181-186.
101. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13(9):1096-1101.
102. Kanda J., Mizumoto C., Kawabata H., et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 2008, 93(10):1550-1554.
103. Tanno T., Rabel A., Lee Y.T., et al. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion 2010, 50(7):1532-1535.
104. Ramirez J.M., Schaad O., Durual S., et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol 2009, 144(2):251-262.
105. Gardenghi S, Ramos P, Follenzi A, et al. Hepcidin and Hfe in iron overload in beta-thalassemia. Ann N Y Acad Sci 2010, 1202:221-225.
106. Nicolas G., Viatte L., Lou D.Q., et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003, 34(1):97-101.
107. Ghoti H., Amer J., Winder A., et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007, 79(6):463-467.
108. Shinar E., Rachmilewitz E.A. Oxidative denaturation of red blood cells in thalassemia. Semin Hematol 1990, 27(1):70-82.
109. Greer E.L., Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24(50):7410-7425.